David R. Epstein
David R. Epstein has made 3 open-market purchases worth $220k since Oct 7, 2026, in 1 company. The latest: $89k of AGMB, filed Oct 22, 2026, scored 40 out of 100.
Director, AgomAb Therapeutics NV
Follow David R. Epstein, freeOpen the live feed
A free account gets an alert the minute a new buy or sale is filed.
Purchases
| Filed | Stock | Stake | Score | Bought | 1 week | 1 month |
|---|---|---|---|---|---|---|
| Oct 22 Form 4 (opens sec.gov) |
AGMBAgomAb Therapeutics NV · DirectorDirector · Near 52-week low | +67% stake | 40 | $89k 10,000 at $8.88 |
−14.1% | waiting |
| Oct 9 Form 4 (opens sec.gov) |
AGMBAgomAb Therapeutics NV · DirectorDirector · 3 insiders buying · Near 52-week low | +50% stake | 62 | $45k 5,000 at $8.90 |
−8.8% | waiting |
| Oct 7 Form 4 (opens sec.gov) |
AGMBAgomAb Therapeutics NV · DirectorDirector · 3 insiders buying · Near 52-week low | New position | 62 | $86k 10,000 at $8.63 |
−1.3% | waiting |
Track record (hypothetical): a week after the filing, these buys averaged −8.1% (0% up, 3 measured).
Questions
What stock has David R. Epstein bought?
AGMB (AgomAb Therapeutics NV), all on the open market and reported on SEC Form 4.
When did David R. Epstein last buy?
Oct 22, 2026: 10,000 shares of AGMB at $8.88, $89k in all (Form 4 (opens sec.gov)).
Has David R. Epstein filed a notice of a planned sale?
Not in the filings on record. A Form 144 is the notice an insider must file before selling restricted or control shares, and it lands on EDGAR before the sale is reported.
Is David R. Epstein a routine or an opportunistic buyer?
There isn't enough history to say yet.
Data as of Oct 22, 2026, from SEC EDGAR Form 4 filings: open-market purchases (code P) of $25,000 or more, and open-market sales. Every row links to its filing. Scores summarise what a filing says (how the score works); outcomes are hypothetical, from the first close after the filing, and past results don't predict future ones. Disclaimer